Key result
High ANGPTL3 levels linked to ~27% higher all-cause mortality.
Why the study?
Does high circulating ANGPTL3 level increase all-cause and cardiovascular mortality in adults without baseline cardiovascular disease or lipid-lowering therapy?
Cohort (n=33,592)
Yes
Does high circulating ANGPTL3 level increase all-cause and cardiovascular mortality in adults without baseline cardiovascular disease or lipid-lowering therapy?
Answers are grounded in this paper and cite their sources.
Higher circulating ANGPTL3 levels are independently associated with increased all-cause and cardiovascular mortality in adults without baseline cardiovascular disease or lipid-lowering therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) conducted a cohort in Without baseline cardiovascular disease or lipid-lowering therapy (n=33,592). High circulating ANGPTL3 level vs. Low circulating ANGPTL3 level was evaluated on All-cause mortality (HR 1.27, 95% CI 1.15-1.41). High circulating ANGPTL3 levels were associated with increased all-cause mortality and cardiovascular mortality compared to low levels.
Synapse has enriched 10 related papers. Consider them for comparative context: